A study led by the University of Barcelona and the Spanish National Research Council's Institute for Advanced Chemistry of Catalonia (IQAC - CSIC) presents a new therapeutic tool capable of inhibiting ...
Researchers have identified a dual therapeutic strategy that combined inhibition of a key SARS-CoV-2 viral enzyme with suppression of a host inflammatory pathway, with preclinical evidence that ...
Researchers from the Institute for Basic Science of Korea and collaborating institutions have designed a new class of peptide-based inhibitors targeting a crucial interface within the SARS-CoV-2 ...
ATLANTA — Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results